Company Overview of ARCA biopharma, Inc.
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. The company has a collaboration agreement with Medtronic, Inc. for the support of Gencaro’s Phase IIB/III clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
11080 CirclePoint Road
Westminster, CO 80020
Key Executives for ARCA biopharma, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $300.7K
Senior Vice President, General Counsel and Secretary
Total Annual Compensation: $285.6K
Compensation as of Fiscal Year 2014.
ARCA biopharma, Inc. Key Developments
ARCA biopharma, Inc. Provides an Update on GENETIC-AF
Jan 12 16
ARCA biopharma, Inc. provided an update on GENETIC-AF, the company's Phase 2B/3 clinical trial evaluating GencaroTM (bucindolol hydrochloride) as a potential genetically-targeted treatment for the prevention of atrial fibrillation. 50 patients have been enrolled in the GENETIC-AF trial. By the end of 2016, the company anticipates enrollment of a sufficient number of patients for the Data Safety Monitoring Board (DSMB) interim analysis of Phase 2B efficacy data. Allowing for patients to complete their 24-week treatment period, the outcome of the DSMB interim analysis is expected in the first half of 2017. There are currently 60 clinical trial sites in the United States and Canada, with 5 additional sites in start-up. GENETIC-AF is a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing the safety and efficacy of Gencaro to Toprol-XL (metoprolol succinate) for the treatment of atrial fibrillation (AF) in patients with heart failure and left ventricular systolic dysfunction (HFREF patients). The primary endpoint of GENETIC-AF is time to symptomatic AF/atrial flutter (AFL). ARCA is enrolling only HFREF patients with the genetic variant of the cardiac beta-1 adrenergic receptor, which the Company believes responds most favorably to Gencaro, the 389 arginine homozygous genotype (ADRB1 Arg389Arg). GENETIC-AF has an adaptive design, under which the company initiated the trial as a Phase 2B trial. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend, based on a comparison to the pre-trial statistical assumptions, whether the trial should proceed to Phase 3. The Company expects GENETIC-AF will enroll a combined 620 patients over the Phase 2B and Phase 3 portions of the trial.
ARCA biopharma, Inc. Presents at 27th Annual Piper Jaffray Healthcare Conference, Dec-01-2015 08:10 AM
Nov 19 15
ARCA biopharma, Inc. Presents at 27th Annual Piper Jaffray Healthcare Conference, Dec-01-2015 08:10 AM. Venue: Lotte New York Palace, New York, New York, United States. Speakers: Thomas A. Keuer, Chief Operating Officer.
ARCA Biopharma, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
Nov 12 15
ARCA biopharma, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported loss from operations of $2,817,000 against $2,285,000 a year ago. Net loss and comprehensive loss was $2,814,000 or $0.31 per basic and diluted share against $2,284,000 or $0.76 per basic and diluted share a year ago.
For the nine months, the company reported loss from operations of $8,280,000 against $7,081,000 a year ago. Net loss and comprehensive loss was $8,277,000 or $1.54 per basic and diluted share against $7,078,000 or $2.44 per basic and diluted share a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 10, 2015